Global Elrantamab Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

According to our (Global Info Research) latest study, the global Elrantamab market size was valued at US$ 313 million in 2025 and is forecast to a readjusted size of US$ 1153 million by 2032 with a CAGR of 12.6% during review period.
Elranatamab is a humanized bispecific monoclonal antibody targeting BCMA/CD3, indicated for the treatment of relapsed or refractory multiple myeloma. The drug can simultaneously bind to BCMA antigen on the surface of myeloma cells and CD3 antigen on the surface of T cells. By bridging tumor cells and T cells, it activates T cells to specifically kill tumor cells. As a T-cell redirecting immunotherapeutic agent, it is characterized by high targeting specificity and significant anti-tumor activity.In 2025, global Elranatamab production reached approximately 51000——52000 vials.
Elranatamab is a humanized bispecific monoclonal antibody targeting BCMA/CD3, mainly used for the treatment of relapsed or refractory multiple myeloma, and is one of the core agents in the field of T-cell redirecting immunotherapy. With a clear mechanism of action, it activates anti-tumor immunity by bridging myeloma cells and T cells. Clinical studies have confirmed that it exhibits deep and durable efficacy in heavily pretreated patients, and is recommended by authoritative guidelines such as the US NCCN and Chinese CSCO, with a clear market positioning.
In terms of the competitive landscape, the drug, together with similar BCMA/CD3 bispecific antibodies including Johnson & Johnson’s Teclistamab, constitutes an important therapeutic option for multiple myeloma, while facing competition from CAR-T therapies. Its differentiation is reflected in its administration route and tolerability profile. Elranatamab has been approved in major markets worldwide including the United States, the European Union and China, with commercial layout covering multiple regions. Continuous clinical development, including combination therapies and exploration of first-line indications, provides long-term momentum for market expansion.
As an important layout of Pfizer in the field of tumor immunology, the drug relies on the company’s marketing channels and R&D resources, and is expected to occupy an important position in the bispecific antibody market for multiple myeloma. Meanwhile, it will promote the popularization and application of BCMA-targeted therapeutic regimens and become a key force in innovating the treatment landscape of this field.
This report is a detailed and comprehensive analysis for global Elrantamab market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Elrantamab market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Elrantamab market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Elrantamab market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Elrantamab market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Elrantamab
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Elrantamab market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Pfizer, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Elrantamab market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
44 mg / 1.1 mL
76 mg / 1.9 mL
Market segment by Dosage Form
Subcutaneous Injection Solution
Lyophilized Powder for Injection
Market segment by Sales Channels
Hospital
Retail
Online
Market segment by Antibody Type
Monoclonal Antibody
Polyclonal Antibody
Bispecific Antibody
Market segment by Application
Monotherapy for Relapsed or Refractory Multiple Myeloma
Combination Therapy with Immunomodulators and Proteasome Inhibitors
Exploration in First-Line or Second-Line Treatment of Multiple Myeloma
Otherts
Major players covered
Pfizer
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Elrantamab product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Elrantamab, with price, sales quantity, revenue, and global market share of Elrantamab from 2021 to 2026.
Chapter 3, the Elrantamab competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Elrantamab breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Elrantamab market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Elrantamab.
Chapter 14 and 15, to describe Elrantamab sales channel, distributors, customers, research findings and conclusion.